« Return to News | Study Conduct | CROs/Service Providers

PRA International Opens Phase I Facility in Hungary

Friday, July 2, 2010 08:03 AM

PRA International, a global CRO, opened a phase I facility in Budapest, Hungary that will provide “unit-on-demand” service.

Situated in a new hospital, the unit contains eight beds and is designed for phase I patient studies. The new phase I unit is accredited, meets Hungarian requirements, and enhances PRA’s ability to provide early-phase services in Hungary.

This opening improves PRA’s ability to accommodate increasing demand from sponsors to conduct phase I trials in patients earlier and more often. Like other PRA facilities in Central and Eastern Europe, the Budapest unit will use its innovative unit-on-demand business model that brings a phase I center to patients.

This model establishes a phase I study environment in central medical facilities that specialize in the treatment of the target patient population. Physicians can recruit high volumes of patients using extensive networks of referring specialists and general practitioners. The studies occur in single-center and multinational settings.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.